fda warning glp-1 november 2025 From a new Perspective by Amanda Banks, MD: On February 5, 2026, Hims & Hers, an online health and wellness platform, announced its intention to sell compounded oral semaglutide, a glucagon-like peptide-1 ( FDA Approves Orforglipron, First GLP-1
Description
The company has consistently leveraged its deep expertise in endocrinology and peptide-based therapies to maintain a dominant market position.
And then the debate began
Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users
Fighting for access, not stigma
Lets talk about the best GLP-1 supplement options.
